The World Health Organization advised doctors against using Gilead Sciences’ antiviral drug remdesivir as a treatment for patients hospitalized with Covid-19.

The WHO Guideline Development Group, a panel of international experts who provide advice to the agency, said its recommendation is based on new data comparing the effects of several drug treatments, including data from four international randomized trials involving more than 7,000 patients hospitalized.

The group said there is currently “no evidence” that it improves survival rates or the need for ventilation.

“After thoroughly reviewing this evidence, the WHO GDG expert panel concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement,” the group wrote in a press release.

The group said there is currently “no evidence” that it improves survival rates or the need for ventilation.

The recommendation was published in the British medical trade journal The BMJ on Friday in the U.K.